Until recently, the main targets of pharUntil recently, the main targets of pharmaceutical advertisements were clinicians maceutical advertisements were clinicians and the major vehicles for 'educational and the major vehicles for 'educational promotion' were advertisements in acapromotion' were advertisements in academic and professional journals and visits demic and professional journals and visits and gifts from pharmaceutical representand gifts from pharmaceutical representatives. All is now changed and patients atives. All is now changed and patients have become legitimate targets of adverhave become legitimate targets of advertising.
Direct-to-consumer advertising tising.
Direct-to-consumer advertising represents a new and expanding area of represents a new and expanding area of pharmaceutical promotion that harnesses pharmaceutical promotion that harnesses the mass media. the mass media.
In the USA, direct-to-consumer adverIn the USA, direct-to-consumer advertising has become a $2.5 billion per year tising has become a $2.5 billion per year business (National Institute of Health Care business (National Institute of Health Care Management, 2001) , and serious concerns Management, 2001) , and serious concerns about its impact on appropriate presabout its impact on appropriate prescribing, health resources and patientcribing, health resources and patientprofessional relations have been voiced professional relations have been voiced (Hoffman & Wilkes, 1999) . Increased sales (Hoffman & Wilkes, 1999) . Increased sales of 50 of the most heavily marketed drugs of 50 of the most heavily marketed drugs were responsible for almost half of the were responsible for almost half of the $20.8 billion increase in spending on $20.8 billion increase in spending on prescription drugs between 1999 and prescription drugs between 1999 (National Institute of Health Care 2000 (National Institute of Health Care Management, 2001 . Management, 2001) .
Patients in the UK and the rest of the Patients in the UK and the rest of the European Union have been 'protected from' European Union have been 'protected from' or 'denied' direct-to-consumer advertising or 'denied' direct-to-consumer advertising (depending on one's perspective) for at least (depending on one's perspective) for at least the next 3 years. Despite this ban, patients the next 3 years. Despite this ban, patients can receive information about new and excan receive information about new and existing treatments and services from a wide isting treatments and services from a wide range of media, and psychotropic brands range of media, and psychotropic brands have become household names. Additionhave become household names. Additionally, the internet has made national restrically, the internet has made national restrictions and regulations seem increasingly tions and regulations seem increasingly irrelevant.
irrelevant.
So what are the costs and consequences So what are the costs and consequences of direct-to-consumer advertising, and what of direct-to-consumer advertising, and what does blurring of the boundaries between does blurring of the boundaries between formal and informal direct-to-consumer formal and informal direct-to-consumer advertising pose for psychiatry? advertising pose for psychiatry?
ARGUMENTS ARGUMENTS FOR AND AGAINST FOR AND AGAINST
Proponents of direct-to-consumer advertisProponents of direct-to-consumer advertising claim that advertisements are a legitiing claim that advertisements are a legitimate source of quality patient information mate source of quality patient information (Bonaccorso & Sturchio, 2002) . Informing (Bonaccorso & Sturchio, 2002) . Informing and empowering patients are major themes and empowering patients are major themes in the new National Health Service. In in the new National Health Service. In psychiatry, the treatments offered have psychiatry, the treatments offered have both benefits and side-effects, and rational both benefits and side-effects, and rational decisions regarding concordance might be decisions regarding concordance might be enhanced through information targeted at enhanced through information targeted at patients. Additionally, many individuals patients. Additionally, many individuals do not seek help for psychiatric conditions, do not seek help for psychiatric conditions, either through stigma or poor knowledge either through stigma or poor knowledge about illness or effective treatments. about illness or effective treatments. Direct-to-consumer advertising might Direct-to-consumer advertising might therefore help to address unmet needs. therefore help to address unmet needs.
Arguments against direct-to-consumer Arguments against direct-to-consumer advertising principally centre on concerns advertising principally centre on concerns about the pharmaceutical industry's ability about the pharmaceutical industry's ability to produce unbiased information. Given to produce unbiased information. Given the nature of market economics, the prithe nature of market economics, the primary aim of advertising campaigns is to mary aim of advertising campaigns is to increase market share and profit, rather increase market share and profit, rather than enhance well-being (Findlay, 2001; than enhance well-being (Findlay, 2001; . Hence, advertisements may . Hence, advertisements may not look at all treatment options, including not look at all treatment options, including non-drug treatments, or provide a consunon-drug treatments, or provide a consumer with comprehensive information on mer with comprehensive information on potential adverse effects. Concerns about potential adverse effects. Concerns about the quality of information in advertisethe quality of information in advertisements are justified, with one in four ments are justified, with one in four products violating US Food and Drug products violating US Food and Drug Admin Administration regulations (Aitken & Holt, istration regulations . 2000).
Hoffman & Wilkes (1999), reflecting Hoffman & Wilkes (1999) , reflecting on the experience in the USA, assert that on the experience in the USA, assert that direct-to-consumer advertising direct-to-consumer advertising 'unreasonablyincreases consumer expectations, 'unreasonablyincreases consumer expectations, forces doctors to spend time disabusing patients forces doctors to spend time disabusing patients of misinformation, diminishes the doctorôf misinformation, diminishes the doctorp atient relationship because a doctor refuses to patient relationship because a doctor refuses to prescribe an advertised drug, or results in poor prescribe an advertised drug, or results in poor practice if the doctor capitulates and prescribes practice if the doctor capitulates and prescribes an inappropriate agent'. an inappropriate agent'.
Research evidence tends to support this Research evidence tends to support this assertion. Mintzes assertion. Mintzes et al et al (2001) have (2001) have compared prescribing patterns and concompared prescribing patterns and consultations in Canada (where direct-tosultations in Canada (where direct-toconsumer advertising is banned) and the consumer advertising is banned) and the USA USA (where it is well established). They (where it is well established). They showed that in the USA patients often reshowed that in the USA patients often requested drugs that were promoted through quested drugs that were promoted through direct-to-consumer advertising and that direct-to-consumer advertising and that clinicians were likely to acquiesce to these clinicians were likely to acquiesce to these requests, despite feeling at best 'ambivalent' requests, despite feeling at best 'ambivalent' about the drug. No empirical research has about the drug. No empirical research has ever demonstrated better communication ever demonstrated better communication and improved health outcomes. Direct-toand improved health outcomes. Direct-toconsumer advertising therefore undermines consumer advertising therefore undermines efforts to improve the efficiency gained efforts to improve the efficiency gained from finite health budgets through costfrom finite health budgets through costconscious guidelines and the use of generic conscious guidelines and the use of generic drugs where branded drugs confer marginal drugs where branded drugs confer marginal benefit. benefit.
DIRECT-TO-CONSUMER DIRECT-TO-CONSUMER ADVERTISING OF ADVERTISING OF PSYCHOTROPICS PSYCHOTROPICS
Psychotropics are heavily marketed, with Psychotropics are heavily marketed, with paroxetine being the fourth most advertised paroxetine being the fourth most advertised of all prescription-only medicines -at a of all prescription-only medicines -at a cost of US$91.8 million in direct-tocost of US$91.8 million in direct-toconsumer advertising alone (National consumer advertising alone (National Institute of Health Care Management, Institute of Health Care Management, 2001) . Direct-to-consumer advertising has 2001). Direct-to-consumer advertising has increased disproportionately among psyincreased disproportionately among psychotropics, with expensive magazine adverchotropics, with expensive magazine advertisements and television commercials. A tisements and television commercials. A few examples of specific campaigns give few examples of specific campaigns give some insight into what we might expect some insight into what we might expect from direct-to-consumer advertising. from direct-to-consumer advertising.
In 1997, Eli Lilly began a US$15-In 1997, Eli Lilly began a US$15-20 million print advertising campaign in 20 million print advertising campaign in major magazines for fluoxetine (Prozac). major magazines for fluoxetine (Prozac). Their advertising text played on negative Their advertising text played on negative public perceptions of benzodiazepines, public perceptions of benzodiazepines, while reassuring readers that Prozac is more while reassuring readers that Prozac is more innocuous: 'It's not a tranquilizer: It won't innocuous: 'It's not a tranquilizer: It won't take away your personality. Depression take away your personality. Depression can do that, but Prozac can't'. Non-drug can do that, but Prozac can't'. Non-drug treatments were presented as a secondary treatments were presented as a secondary measure for use after a patient had begun measure for use after a patient had begun to respond to fluoxetine, rather than as a to respond to fluoxetine, rather than as a genuine alternative (source: Advertisement genuine alternative (source: Advertisement for Prozac. for Prozac. Cosmopolitan Cosmopolitan, US edition, , US edition, September 1997). Other campaigns have September 1997). Other campaigns have specifically targeted the use of generic drugs specifically targeted the use of generic drugs and the risk of 'generic substitution', asking and the risk of 'generic substitution', asking patients to insist on a specific drug 'by name'. patients to insist on a specific drug 'by name'.
ADVERTISING, PATIENT ADVERTISING, PATIENT EDUCATION AND PATIENT EDUCATION AND PATIENT CARE^BLURRING THE CARE^BLURRING THE BOUNDARIES BOUNDARIES
The Association of British Pharmaceutical The Association of British Pharmaceutical Industries (ABPI) has reformulated the Industries (ABPI) has reformulated the 1 1
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E D I T O R I A L E D I T O R I A L
Direct-to-consumer advertising of psychotropics Direct-to-consumer advertising of psychotropics What might we expect in psychiatry when What might we expect in psychiatry when the boundaries between patient education, the boundaries between patient education, advertisement and patient care become advertisement and patient care become blurred? Some examples should make us blurred? Some examples should make us concerned. concerned.
The advent of patient information The advent of patient information groups and the ready access that they progroups and the ready access that they provide to consumers has been harnessed by vide to consumers has been harnessed by the pharmaceutical industry. Marc Czarka, the pharmaceutical industry. Marc Czarka, a director for Eli Lilly in the Benelux, said a director for Eli Lilly in the Benelux, said in 1997 that Lilly funds the American Psyin 1997 that Lilly funds the American Psychiatric Association and it sponsors and chiatric Association and it sponsors and helped to create the Belgian League of helped to create the Belgian League of Depression in 1995. 'It's useful for us beDepression in 1995. 'It's useful for us because, unlike American law, European law cause, unlike American law, European law does not allow us to talk directly to potendoes not allow us to talk directly to potential patients. . . .The league does it for us' tial patients. . . .The league does it for us' (cited in . Examples of (cited in . Examples of more direct influence over individual pamore direct influence over individual patient care have also been seen in the USA. tient care have also been seen in the USA. Janssen-Cilag has developed a programme Janssen-Cilag has developed a programme of information leaflets, telephone support of information leaflets, telephone support and crisis intervention, but only to those and crisis intervention, but only to those in receipt of their product, risperidone. in receipt of their product, risperidone. The 'person to person' programme was The 'person to person' programme was launched, with a good deal of support from launched, with a good deal of support from both the largest US patient representative both the largest US patient representative group (the National Alliance for the Mengroup (the National Alliance for the Mentally Ill) and the American Psychiatric Assotally Ill) and the American Psychiatric Association. In the UK, a similar collaborative ciation. In the UK, a similar collaborative initiative exists with the National Institute initiative exists with the National Institute of Mental Health's '1 in 100' campaign, of Mental Health's '1 in 100' campaign, which is dedicated to helping 'people with which is dedicated to helping 'people with schizophrenia, their families and friends' schizophrenia, their families and friends' (ABPI, 2002) . (ABPI, 2002) .
One widely publicised development in One widely publicised development in quasi-direct-to-consumer advertising has quasi-direct-to-consumer advertising has been 'celebrity endorsement'. Ricky been 'celebrity endorsement'. Ricky Williams, an American football player, regWilliams, an American football player, regularly appears on television to discuss his ularly appears on television to discuss his 'social anxiety disorder', while being paid 'social anxiety disorder', while being paid by GlaxoSmithKline to publicise their proby GlaxoSmithKline to publicise their product, paroxetine. In an industry website, duct, paroxetine. In an industry website, Williams says: 'It's amazing at how much Williams says: 'It's amazing at how much I've grown and how much I've changed I've grown and how much I've changed and how much I went through. And of and how much I went through. And of course I owe a lot of that to Janey, my course I owe a lot of that to Janey, my 
WHAT IS TO BE DONE ? WHAT IS TO BE DONE ?
Direct-to-consumer advertising exploits an Direct-to-consumer advertising exploits an information void that has been left by clininformation void that has been left by clinicians, health care providers and policy maicians, health care providers and policy makers. Creating more informed patients is an kers. Creating more informed patients is an aspiration with which no reasonable cliniaspiration with which no reasonable clinician can argue. This is especially needed cian can argue. This is especially needed in psychiatry, where stigma and misconcepin psychiatry, where stigma and misconceptions about the value of drug treatments tions about the value of drug treatments contribute to poor compliance or prevent contribute to poor compliance or prevent patients from seeking help. Whether formal patients from seeking help. Whether formal or informal direct-to-consumer advertising or informal direct-to-consumer advertising fills this void with unbiased information is fills this void with unbiased information is far from clear. In fact the opposite is likely far from clear. In fact the opposite is likely to be true. Canada, which despite its geoto be true. Canada, which despite its geographical proximity to the USA has thus graphical proximity to the USA has thus far resisted formal direct-to-consumer far resisted formal direct-to-consumer advertising, has funded research into the advertising, has funded research into the costs and consequences of such advertising. costs and consequences of such advertising. Mintzes, the author of this work, Mintzes, the author of this work, concluded: concluded:
'We could find no evidence of improved drug uti-'We could find no evidence of improved drug utilization, improved doctor/patient relations, or lization, improved doctor/patient relations, or reductions in hospitalization rates, serious reductions in hospitalization rates, serious morbidity or mortality attributable to [directmorbidity or mortality attributable to [directto-consumer advertising] . The aim of the prohito-consumer advertising]. The aim of the prohibition of prescription drug advertising in Canada bition of prescription drug advertising in Canada is health protection. Any legislative change that is health protection. Any legislative change that would weaken the current restrictions on such would weaken the current restrictions on such advertising should be based on strong evidence advertising should be based on strong evidence that concerns about potential harm are unthat concerns about potential harm are unfounded, and^ideally^evidence of health founded, and^ideally^evidence of health benefits. On the contrary, we found a considerbenefits. On the contrary, we found a considerable body of evidence suggesting that such conable body of evidence suggesting that such concerns are warranted, and no evidence that cerns are warranted, and no evidence that [direct-to-consumer New England Journal of Medicine of Medicine said 'The education of said 'The education of patients -or physicians -is too important patients -or physicians -is too important to be left to the pharmaceutical industry'. to be left to the pharmaceutical industry'. Wolfe called on the National Institutes of Wolfe called on the National Institutes of Health and the US Food and Drug AdminHealth and the US Food and Drug Administration to 'replace tainted drug company istration to 'replace tainted drug company ''education'' with scientifically based, use-''education'' with scientifically based, useful information that will stimulate better ful information that will stimulate better conversations between doctors and patients conversations between doctors and patients and lead to true empowerment' (Wolfe, and lead to true empowerment' .
We believe that the advent of direct-toWe believe that the advent of direct-toconsumer advertising should not be seen as consumer advertising should not be seen as progress. Psychiatry is likely to be changed progress. Psychiatry is likely to be changed for the worse and patient care is likely to be for the worse and patient care is likely to be compromised as a consequence. There recompromised as a consequence. There remains an onus on us all to strive to produce mains an onus on us all to strive to produce more informed patients and to provide unmore informed patients and to provide unbiased information that is understandable biased information that is understandable and informative for those who require our and informative for those who require our care. care.
